167073-19-0

Usage

Uses

Used in Pharmaceutical Industry:
Pitavastatin Ethyl Ester is used as a pharmaceutical agent for the treatment of hyperlipidemia, a condition characterized by high levels of lipids, particularly cholesterol, in the blood. It is particularly effective in reducing LDL cholesterol, which is a major risk factor for atherosclerosis and coronary heart disease.
Used in Chemical Synthesis:
Pitavastatin Ethyl Ester is used as a reactant in an improved process for preparing quinoline derivatives. Quinolines are an important class of heterocyclic compounds with a wide range of applications in various fields, including pharmaceuticals, agrochemicals, and materials science. The use of Pitavastatin Ethyl Ester in this process enhances the synthesis of quinoline derivatives, potentially leading to the development of new and more effective drugs and materials.

InChI:InChI=1/C11H23Cl2N2O2PS/c1-3-10-19-11-4-9-17-18(16,14(11)2)15(7-5-12)8-6-13/h11H,3-10H2,1-2H3

Upstream product

• 254452-91-0 ethyl 5(S)-(E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl]-5-hydroxy-3-oxo-6-heptenoate 
• 477950-34-8 ethyl (E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl]-3,5-dihydroxyhept-6-enoate 
• 64-17-5 ethanol 
• 147526-32-7 pitavastatin 
• 1403338-19-1 methyl (2E)-3-[2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-yl]acrylate 
• 1403338-24-8 ethyl (5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-yl]-5-(tert-butyldimethylsilyloxy)-3-oxo-6-heptenoate 
• 1403338-27-1 C₂₉H₃₄FNO₃Si 
• 222306-19-6 (3S,4E)-5-[2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-yl]-3-hydroxypentenoic acid 
• 1403338-23-7 C₃₂H₃₆FN₃O₂Si 
• 1403338-21-5 (3S,4E)-5-[2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-yl]-3-hydroxypentenoic acid (R)-α-methylbenzylamine salt 
• 1403338-20-4 (1S)-2-hydroxy-1,2,2-triphenylethyl (4E)-5-[2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-yl]-3-hydroxy-4-pentenoate 
• 121660-37-5 2-cyclopropyl-4-(4-fluorophenyl)-3-formylquinoline 
• 166803-31-2 (E)-7-[2-cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-3,5-dioxo-hept-6-enoic acid ethyl ester 
• 254452-95-4 ethyl 5(R)-(E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl]-5-hydroxy-3-oxo-6-heptenoate 

Downstream Products

• 574705-92-3 sodium (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate 
• 147526-32-7 pitavastatin calcium salt 
• 1403338-25-9 ethyl (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-yl]-3,5-dihydroxy-6-heptenoate, trifluoroacetate salt 
• 147526-32-7 pitavastatin 

Relevant academic research and scientific papers

Virtual screening and experimental validation identify novel modulators of nuclear receptor RXRα from Drugbank database

Retinoid X receptor alpha (RXRα), an important ligand-dependent transcription factor, plays a critical role in the development of various cancers and metabolic and neurodegenerative diseases. Therefore, RXRα represents one of the most important targets in modern drug discovery. In this study, Drugbank 2.0 with 1280 old drugs were virtually screened by Glide according to the crystal structure of ligand-binding domain (LBP) of RXRα. 15 compounds selected were tested for their binding and transcriptional activity toward RXRα by Biacore and reporter gene assay, respectively. The identified new scafford ligand of RXRα, Pitavastatin (1), was chemically optimized. Our results demonstrated that statin compounds Pitavastatin (1) and Fluvastatin (4) could bind to the LBP of RXRα (KD = 13.30 μM and 11.04 μM, respectively) and serve as transcriptional antagonists of RXRα. On the contrary, compound (12) (domperidone) and (13) (rosiglitazone maleate) could bind to the LBP of RXRα (KD = 8.80 μM and 15.01 μM, respectively) but serve as transcriptional agonists of RXRα.

METHOD FOR PRODUCING PITAVASTATIN CALCIUM

Production of pitavastatin calcium safely on an industrial scale with a high yield and high selectivity at low cost. A method of producing pitavastatin calcium including step (i) for acetalizing a compound represented by the formula (1) to give a compound represented by the formula (3), step (ii) for reacting a compound represented by the formula (3) with an acid to give a compound represented by the formula (4), and step (iii) for hydrolyzing a compound represented by the formula (4) and reacting same with a calcium compound.

PROCESS FOR PREPARING QUINOLINE DERIVATIVE

The present invention relates to a novel process for preparing Pitavastatin calcium salt of formula (I).

Process for producing (3R,5S)-(E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-quinolin- 3-yl]-3, 5-dihydroxyhept-6-enic acid esters

A process for producing a compound represented by the following formula (IV): (wherein R denotes a hydrogen atom, an alkyl group, or an aryl group), comprising reducing a compound selected from the group consisting of: a compound represented by the following formula (I): (wherein R is as defined in the formula); a compound represented by the following formula (II): (wherein R is as defined in the formula); and a compound represented by the following formula (III): (wherein R is as defined in the formula), by reacting the compound with a cell of a microorganism and/or a cell preparation thereof capable of stereo-selectively reducing a keto group.

METHOD FOR PREPARING 7-QUINOLINYL-3,5-DIHYDROXYHEPT-6-ENOATE

A method for preparing a 7-quinolynyl-3,5-dihydroxyhept-6-enoate useful as an intermediate for pharmaceuticals, in high yield and in high purity, is presented. It is a method for preparing a 7-quinolinyl-3,5-dihydroxyhept-6-enoate represented by the formu

Process for the manufacture of organic compounds

A method for preparing an alkali metal salt comprising: (a) condensing a disilyloxydiene with an aldehyde in the presence of a titanium (IV) catalyst in an inert solvent to form a 5(S)-hydroxy-3-ketoester; (b) reducing the 5(S)-hydroxy-3-ketoester to a 3(

Enantioselective addition of diketene to aldehydes promoted by chiral Schiff base-titanium alkoxide complex. Application to asymmetric synthesis of potential inhibitors of HMG coenzyme reductase

Highly enantioselective addition of diketene to aldehydes was achieved by using novel Schiff base-titanium alkoxide complexes. Up to 92% ee of 5-hydroxy-3-oxoesters was obtained. This procedure provides an efficient method for the asymmetric synthesis of potential inhibitors of HMG coenzyme reductase.